These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 3840655)
1. Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs. Schwartz J; Liard JF; Ott C; Cowley AW Am J Physiol; 1985 Nov; 249(5 Pt 2):H1001-8. PubMed ID: 3840655 [TBL] [Abstract][Full Text] [Related]
2. Role of antidiuretic activity in the inhibition of renin secretion by vasopressin in anesthetized dogs. Schwartz J; Ott C; Morales O; Reid IA Peptides; 1986; 7(1):91-6. PubMed ID: 3520511 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin. Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923 [TBL] [Abstract][Full Text] [Related]
4. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin. Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979 [TBL] [Abstract][Full Text] [Related]
5. Role of the vasoconstrictor and antidiuretic activities of vasopressin in inhibition of renin secretion in conscious dogs. Schwartz J; Reid IA Am J Physiol; 1986 Jan; 250(1 Pt 2):F92-6. PubMed ID: 3510566 [TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs. Liard JF; Spadone JC J Cardiovasc Pharmacol; 1984; 6(4):713-9. PubMed ID: 6206331 [TBL] [Abstract][Full Text] [Related]
7. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs. Liard JF Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987 [TBL] [Abstract][Full Text] [Related]
9. V1 vs. combined V1+V2 vasopressin blockade after hemorrhage in conscious dogs. Liard JF Am J Physiol; 1988 Dec; 255(6 Pt 2):H1325-9. PubMed ID: 2974249 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin. Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076 [TBL] [Abstract][Full Text] [Related]
11. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4. Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045 [TBL] [Abstract][Full Text] [Related]
12. Vasopressin-induced antipyresis in the medial amygdaloid nucleus of conscious rats. Federico P; Veale WL; Pittman QJ Am J Physiol; 1992 May; 262(5 Pt 2):R901-8. PubMed ID: 1534208 [TBL] [Abstract][Full Text] [Related]
13. Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin. Ishikawa S; Kim JK; Schrier RW Am J Physiol; 1983 Nov; 245(5 Pt 1):R713-9. PubMed ID: 6688929 [TBL] [Abstract][Full Text] [Related]
14. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4. Manning M; Olma A; Klis WA; Seto J; Sawyer WH J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916 [TBL] [Abstract][Full Text] [Related]
15. Design of more potent antagonists of the antidiuretic responses to arginine-vasopressin. Manning M; Olma A; Klis WA; Kolodziejczyk AM; Seto J; Sawyer WH J Med Chem; 1982 Jan; 25(1):45-50. PubMed ID: 7086821 [TBL] [Abstract][Full Text] [Related]
16. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular effects associated with antidiuretic activity of vasopressin after blockade of its vasoconstrictor action in dehydrated dogs. Liard JF Circ Res; 1986 May; 58(5):631-40. PubMed ID: 3754791 [TBL] [Abstract][Full Text] [Related]
18. Antagonism of vasopressin-induced coronary artery constriction by the vasopressin antagonist d(CH2)5Tyr(Me)-AVP. Kopia GA; Valocik RE J Cardiovasc Pharmacol; 1985; 7(5):958-63. PubMed ID: 2413308 [TBL] [Abstract][Full Text] [Related]
19. Characterization of acute hemodynamic effects of antidiuretic agonists in conscious dogs. Liard JF J Cardiovasc Pharmacol; 1988 Feb; 11(2):174-80. PubMed ID: 2452311 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of the receptors which mediate the stimulation of ACTH secretion by vasopressin in conscious dogs. Schwartz J; Reid IA Neuroendocrinology; 1986; 42(2):93-6. PubMed ID: 3005898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]